Seeking Alpha

Aratana announces top-line results for dog osteoarthritis treatment

  • Aratana Therapeutics (PETX) says dogs that received AT-001 in a dose-ranging study of osteoarthritis "demonstrated improvements in pain assessment scores that were statistically significant compared to placebo."
  • The company plans to move the drug into a pivotal study next year and expects approval in 2016. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: